U.S. Household Products Stock News

BeOne Medicines (ONC) has drawn investor attention after its rebrand from BeiGene, Ltd. to BeOne Medicines AG in May 2025. The change highlights a broad oncology portfolio across commercial, clinical, and preclinical cancer therapies. See our latest analysis for BeOne Medicines. After the rebrand, BeOne Medicines’ share price has been under pressure in the short term, with a 7 day share price return of a 15.18% decline and a 30 day share price return of a 7.64% decline. Its 1 year total...

Procter & Gamble (PG) is back in the spotlight after quarterly results that met revenue expectations, exceeded EBITDA forecasts, and kept full year guidance intact, alongside fresh product launches in its key laundry brands. See our latest analysis for Procter & Gamble. At a share price of $163.51, Procter & Gamble has seen a 7.74% 1 month share price return and a 12.10% 3 month share price return, while its 1 year total shareholder return of 4.32% decline contrasts with a 45.70% gain over...

In recent months, BellRing Brands has reinforced its position in the protein-based nutrition market, with its Premier Protein and Dymatize lines supporting solid revenue and profit growth alongside resilient net margins. This performance highlights how premium branding, focused product specialization, and a broad lineup are helping the company strengthen its competitive position in a crowded category. We’ll now examine how this strong momentum in protein-based nutrition, supported by...

CoStar Group reported fourth-quarter 2025 revenue of US$900 million, up from US$709 million a year earlier, while net income declined to US$47 million from US$60 million, and it concurrently rolled out Homes AI, a Microsoft Azure OpenAI-powered, conversational home-search experience on Homes.com. Amid mixed analyst reactions to recent earnings and guidance, President and CEO Andrew Florance’s purchase of 55,720 shares stands out as a rare insider buy after a year dominated by insider...

Morgan Stanley’s recent call naming Citigroup (C) as its top pick has renewed attention on the bank’s stock, as investors weigh ongoing transformation efforts, cost discipline, and the upcoming May 7 investor day. See our latest analysis for Citigroup. Citigroup’s recent 1-day share price return of 1.14% and 90-day share price return of 8% come after inflation driven credit risk worries briefly knocked sentiment. The 1-year total shareholder return of 48.18% shows that momentum has been...

Imperial Petroleum Inc. has announced it will release its fourth-quarter and full-year 2025 results on 6 March 2026, followed by a management conference call, and is moving ahead with plans to grow its fleet from 20 to 26 vessels totaling about 1.5 million deadweight tons. This combination of upcoming financial disclosure and substantial fleet expansion highlights a meaningful shift in the company’s operational scale and future capacity profile. With Imperial Petroleum preparing to expand...

If you are wondering whether Aramark is fairly priced today or if there is still room for value, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$41.26, with returns of 1.7% over 7 days, 7.2% over 30 days, 12.8% year to date and 15.9% over 1 year, plus 3 year and 5 year returns of 51.7% and 43.7% respectively. Recent news coverage around Aramark has largely focused on its position in the outsourced services and facilities...

In late February 2026, Kymera Therapeutics reported a wider full-year 2025 net loss of US$311.35 million and loss per share of US$3.69, while simultaneously filing a US$392.14 million shelf registration linked to an ESOP offering and a US$500 million at-the-market equity program. Alongside these financings, Kymera advanced its oral STAT6 and IRF5 degrader programs, added veteran developer Neil Graham as Chief Development Officer, and maintained strong backing from major pharma collaborators...

First Interstate BancSystem (FIBK) has come under pressure after hotter than expected inflation data and rising credit risk concerns pushed regional bank shares lower. This has prompted investors to reassess sector valuations and risk exposure. See our latest analysis for First Interstate BancSystem. The recent easing of inflation and credit concerns follows a mixed period for the stock, with a 7.32% 90-day share price return and a 22.14% 1-year total shareholder return contrasting with...

Danaos (DAC) has just filed an omnibus shelf registration, covering potential offerings of common and preferred stock, debt securities, warrants and other instruments, a move that gives management broad future financing flexibility. See our latest analysis for Danaos. The shelf registration comes after a strong run in the shares, with a 7 day share price return of 8.95% and a year to date share price return of 24.18%. The 1 year total shareholder return of 58.92% and 5 year total shareholder...

Viatris (VTRS) has drawn fresh attention after a busy February that combined its fourth quarter and full year 2025 results, new 2026 revenue guidance, an affirmed dividend policy, and progress on an eye-care drug filing. See our latest analysis for Viatris. The recent earnings update, new 2026 revenue guidance and FDA review of MR-141 appear to have reset expectations, with a 30 day share price return of 19.94% and a 1 year total shareholder return of 76.82% pointing to strong, building...

In February 2026, Louisiana-Pacific Corporation reported fourth-quarter 2025 results showing sales of US$567 million and a net loss of US$8 million, alongside full-year 2025 sales of US$2.71 billion and net income of US$146 million, and confirmed the completion of a US$73.13 million share repurchase program originally announced in May 2024. The company also issued 2026 guidance pointing to Siding segment net sales of about US$350 million to US$355 million for the first quarter and about...

AtriCure (ATRC) just reported fourth quarter and full year 2025 results that show higher sales and a shift to quarterly profitability, along with 2026 guidance that calls for revenue growth and positive full year net income. See our latest analysis for AtriCure. Even with the stronger quarterly results and 2026 guidance, AtriCure’s recent share price performance has been weak. The 30 day share price return shows a 16.25% decline and the 1 year total shareholder return reflects a 20.61% loss,...

MYR Group Inc. reported fourth-quarter 2025 sales of US$973.54 million and net income of US$36.55 million, with full-year 2025 sales of US$3.66 billion and net income of US$118.42 million, all higher than the prior year. The sharp improvement in basic earnings per share from continuing operations, rising to US$2.35 for the quarter and US$7.57 for the year, highlights materially higher profitability versus 2024. We’ll now consider how this step-up in earnings and profitability could influence...

In recent months, PVH has reported falling constant currency revenue alongside weak free cash flow margins and declining return on invested capital, raising fresh concerns about its long-term business outlook. This combination of softening demand indicators and strained profitability metrics highlights how pressure on both growth and capital efficiency may be reshaping expectations for the company’s future. Now, we’ll examine how weakening constant currency revenue trends fit with PVH’s...

Crane NXT (CXT) recently hosted its Analyst and Investor Day, giving the market an updated look at its operations after reporting 10% year over year sales growth and higher full year sales growth guidance. See our latest analysis for Crane NXT. At a share price of $48.66, Crane NXT’s short term share price return has been weak, with a 13.11% decline over 90 days and a 9.70% fall in 1 year total shareholder return, while the Antares Vision acquisition and higher sales growth guidance keep...

Johnson & Johnson (JNJ) is back in focus after releasing preliminary Phase 1b data on pasritamig plus docetaxel in metastatic castration-resistant prostate cancer, showing high PSA response rates and a safety profile aligned with docetaxel alone. See our latest analysis for Johnson & Johnson. At a share price of $248.56, Johnson & Johnson has seen a 30-day share price return of 9.38% and a year to date share price return of 19.87%. Its 1-year total shareholder return of 52.73% and 3-year...

Phibro Animal Health (PAHC) is in focus after reporting fiscal Q2 2026 results that significantly beat earnings and revenue expectations, prompting the company to raise full year revenue guidance for investors watching the stock. See our latest analysis for Phibro Animal Health. At a latest share price of $54.54, Phibro Animal Health has seen strong momentum recently, with a 35.84% 1 month share price return and a 46.22% year to date share price return. Its 1 year total shareholder return of...

Why Arbor Realty Trust stock is back in focus Arbor Realty Trust (ABR) is back on many investors’ radars after fourth quarter results showed revenue above expectations, fee based servicing growth, executive appointments and a reaffirmed cash dividend, alongside weaker GAAP earnings and net income. See our latest analysis for Arbor Realty Trust. The share price has responded to the earnings beat, executive hires and affirmed dividend, with an 8.32% 1 day and 15.77% 7 day share price return,...

Why the Procore partnership is drawing fresh attention to United Rentals stock United Rentals (URI) is back on investors’ radar after announcing a new partnership with Procore Technologies that connects its rental equipment data directly into Procore’s Resource Management software. The move ties United Rentals’ telematics feed into Procore’s planning tools, giving shared customers a single view of equipment, labor and materials, and positioning the rental giant more firmly inside day-to-day...

If you are wondering whether V2X at around US$70.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stock has returned 4.5% over the last 7 days, 3.1% over the last month, 27.7% year to date and 55.0% over the past year, which naturally raises questions about what is already baked into the current price. Recent coverage has focused on V2X as a capital goods company listed on the NYSE under the ticker VVX. Investors are paying close attention to how it...

IQVIA Holdings (IQV) is back in focus after its fourth quarter earnings, as several major banks kept positive ratings while trimming valuation models to reflect artificial intelligence risks and recent changes to how the business is segmented. See our latest analysis for IQVIA Holdings. At a share price of US$174.27, IQVIA has experienced a 24.28% one-month share price decline and a 22.67% year-to-date share price decline. The one-year total shareholder return of a 5.72% loss points to fading...

Symbotic recently reported its first-quarter fiscal 2026 results, showing strong revenue growth and profitability that exceeded expectations, supported by improved margins. Management’s emphasis on operational execution, product innovation, and rising deployments highlights how its warehouse automation platform is translating into tangible economic benefits. We’ll now explore how Symbotic’s stronger-than-expected profitability and confident outlook may influence its investment narrative and...

If you are wondering whether TransDigm Group's current share price fairly reflects the business, this article is designed to help you think through that question step by step. The stock last closed at US$1,316.26, with returns of 1.6% over 7 days, a 7.8% decline over 30 days, a 3.1% decline year to date, 2.6% over 1 year, 99.9% over 3 years and 161.2% over 5 years. Recent share price moves sit against a backdrop of ongoing interest in TransDigm Group as a major US capital goods name...